Clinical trials and late‐stage drug development for A lzheimer's disease: an appraisal from 1984 to 2014
University of Southern California · Stockholm University · +10 more institutions
Abstract
The modern era of drug development for Alzheimer's disease began with the proposal of the cholinergic hypothesis of memory impairment and the 1984 research criteria for Alzheimer's disease. Since then, despite the evaluation of numerous potential treatments in clinical trials, only four cholinesterase inhibitors and memantine have shown sufficient safety and efficacy to allow marketing approval at an international level. Although this is probably because the other drugs tested were ineffective, inadequate clinical development methods have also been blamed for the failures. Here, we review the development of treatments for Alzheimer's disease during the past 30 years, considering the drugs, potential targets,…
Citation impact
- FWCI
- 39.47
- Percentile
- 100%
- References
- 172
Authors
11- LSL. S. SchneiderCorresponding
University of Southern California
- FMFrancesca Mangialasche
Stockholm University, University of Perugia, Karolinska Institutet
- NCNancy C. Andreasen
Karolinska University Hospital, Karolinska Institutet
- HFHoward Feldman
University of British Columbia
- EGEzio Giacobini
University of Geneva, University Hospital of Geneva
Topics & keywords
- Clinical trial
- Medicine
- Disease
- Drug development
- Intensive care medicine
- Memantine
- Donepezil
- Drug